Next Up For Cubist: A Future That Includes Optimer, Trius
Cubist Pharmaceuticals will strengthen its position in the challenging antibiotic market with the acquisitions of two rivals, Optimer Pharmaceuticals and Trius Therapeutics. But it was Cubist’s current strength that allowed it to get those deals done on favorable, risk-sharing terms.
You may also be interested in...
Biopharma Dealmaking Quarterly Statistics, Q3 2013
Biopharma financing in Q3 2013 totaled $4.6 billion, a 58% drop from the second quarter; Perrigo’s $8.3 billion acquisition of Elan made up more than half of the M&A dollar value; and marketed products made up the majority of licensed products.
Merck’s “Beyond The Pill” Bet, Vree Health, Goes Commercial
Vree Health, one of the independent subsidiaries Merck is fostering through its innovation ventures initiative, is moving into commercial phase, as it builds a business model that focuses on helping providers meet key goals of health care reform: higher quality and more cost-effective patient care.
Financings Of The Fortnight: Is Google/Calico The Start Of A Wave Of Funding Alternatives?
As survey respondents broadly expect venture capital activity to wane in the coming years, are Google and their like pointing to the next way of financing life sciences innovation? Plus news on recent financings by Civitas Therapeutics, DRI Capital, Five Prime Therapeutics and Cubist Pharmaceuticals.